论文部分内容阅读
目的：探讨谷胱甘肽Ｓ－转移酶π型（ＧＳＴ－π）在卵巢恶性肿瘤组织中的表达及其与肿瘤内在性耐药和患者预后的关系。方法：应用免疫组化ＳＰ法检测４５份卵巢恶性肿瘤组织和１０份正常卵巢组织中ＧＳＴ－π的表达，结合肿瘤细胞体外药物敏感试验结果和患者２ａ随访结果。结果：１．４５份卵巢恶性肿瘤组织ＧＳＴ－π阳性表达率为１００％，１０份正常卵巢组织仅２份呈弱阳性。２．１８份卵巢恶性肿瘤组织ＧＳＴ－π染色程度（＋）、（）、（）三组之间阿霉素对肿瘤细胞的抑制率有统计学差异（Ｐ＜０．０５），其中（）组抑制率明显低于（＋）组（Ｐ＜０．０５）。其余５种药物对肿瘤细胞抑制率差异无显著性（均Ｐ＞０．０５）。３．２８例Ⅲ期卵巢上皮性癌患者２ａ存活率为３９．３％，存活时间≥２ａ和＜２ａ两组ＧＳＴ－π表达差异有显著性（Ｐ＜０．０１），前者染色程度明显弱于后者。结论：ＧＳＴ－π表达在卵巢恶性肿瘤对阿霉素内在性耐药中起重要作用，而与顺铂、卡铂、５－ＦＵ、更生霉素、长春新碱内在性耐药无关。ＧＳＴ－π表达高提示卵巢癌患者预后差，可供临床评价患者预后时参考。
Objective: To investigate the expression of glutathione S-transferase π (GST-π) in ovarian cancer tissue and its relationship with intrinsic tumor resistance and prognosis. Methods: The expression of GST-π in 45 ovarian cancer tissues and 10 normal ovarian tissues was detected by immunohistochemical SP method. Combined with the drug sensitivity test results of tumor cells in vitro and the follow-up results of patients 2a. Results: The positive expression rate of GST-π in 1.45 ovarian cancer tissues was 100%, while only 2 of 10 normal ovarian tissues were weakly positive. There was a significant difference (P <0.05) in the inhibitory rate of doxorubicin between the three groups (P <0.05) in 2.18 ovarian cancer tissues with GST-π staining (+), () group was significantly lower than the inhibition rate (+) group (P <0.05). The remaining five kinds of drugs on tumor cell inhibition rate difference was not significant (P> 0.05). Survival rate was 39.3% in 3.28 cases with stage Ⅲ ovarian epithelial carcinoma, and there was a significant difference in the expression of GST-πbetween survival time≥2a and <2a (P <0.01). The former had a significantly lower staining rate In the latter. Conclusion: The expression of GST-π plays an important role in the resistance of adriamycin to malignant ovarian tumors, but not with the intrinsic resistance to cisplatin, carboplatin, 5-FU, dactinomycin and vincristine. GST-π high expression of ovarian cancer prompted poor prognosis for clinical evaluation of patients with prognosis for reference.